Agathos Biologics to present data on AE1-BHK cell line for viral vector production

Company to show production of multiple serotypes of recombinant adeno-associated viral (rAAV) vectors and rAAV production in suspension-adapted cell line AE1-BHK-S

Morphology of adherent AE1-BHK (A) and suspension AE1-BHK-S (B) cells at 40X magnification

Agathos Biologics, a genetic medicine biotechnology company, will present data at the 27th Annual Meeting of the American Society of Gene and Cell Therapy on its proprietary AE1-BHK cell line for rAAV production. The poster titled “AE1-BHK Novel Cell Line for rAAV Production of Multiple Serotypes for Gene Therapy Applications”, number 1539, will show data from the adherent AE1-BHK cell line and the poster titled “Establishment of Serum Free Suspension Adapted AE1-BHK-S Novel Cell Line for the Manufacturing of rAAV”, number 1540, will show data from the adaptation of the AE1-BHK cell line to suspension culture, referred to as AE1-BHK-S. These posters will be presented during the poster session “AAV Vectors – Product Development and Manufacturing and Approval Considerations” from 12:00 – 7:00 PM on Friday, May 10.

“We are excited to present data on our continued development of the AE1-BHK cell line,” said James Brown, CEO of Agathos Biologics. “These data show the potential of AE1-BHK as a research tool and biomanufacturing platform. We aim to provide researchers, manufacturers, healthcare providers, and patients, with alternatives for genetic medicine that enhance current approaches and avoid ethical issues. Earlier this year, we launched our custom rAAV production service and fulfilled our first order. We plan to expand our rAAV offerings to include off-the-shelf control and reporter vectors and rAAV reference standards.”

Agathos has submitted a patent application for the cell line and provisional patent applications for related technologies. “We are looking for partners and collaborators who will work with us to develop these products,” Brown added. “Working with those who share our vision of expanding access to these advanced treatments is the best way to make a positive impact on genetic medicine. We will be at booth 2384 at the ASGCT Annual Meeting May 7-11, 2024, in Baltimore, MD, and look forward to discussing our results with attendees.” For more information on the AE1-BHK cell line and to inquire about partnerships, please visit AE1-BHK cell line : Agathos Biologics.